Stay updated on Subcutaneous Lirentelimab in Urticaria: Clinical Trial
Sign up to get notified when there's something new on the Subcutaneous Lirentelimab in Urticaria: Clinical Trial page.

Latest updates to the Subcutaneous Lirentelimab in Urticaria: Clinical Trial page
- CheckyesterdayChange DetectedThe page metadata now shows Revision: v3.5.0, replacing Revision: v3.4.3.SummaryDifference0.0%

- Check8 days agoChange DetectedSite revision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check15 days agoNo Change Detected
- Check22 days agoNo Change Detected
- Check37 days agoChange DetectedAdded Revision: v3.4.2 and removed the prior government funding operating-status notice (and Revision: v3.4.1). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check44 days agoChange DetectedNew site-wide notice about government funding and NIH Clinical Center status appears, and the page revision is updated to v3.4.1; core study content remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check51 days agoChange DetectedShow glossary toggle was added and a revision indicator (Revision: v3.4.0) appears on the page. QC-related labels and policy wording were updated (e.g., 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data').SummaryDifference0.1%

- Check65 days agoChange DetectedThe page now shows Revision: v3.3.4, replacing Revision: v3.3.3. This update appears to be a metadata/version tag and does not modify core study content.SummaryDifference0.0%

Stay in the know with updates to Subcutaneous Lirentelimab in Urticaria: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Subcutaneous Lirentelimab in Urticaria: Clinical Trial page.